ACTRN12615000678594招募中1 期
Mesenchymal Stem Cells to prevent ischaemia reperfusion injury in deceased donor renal transplant recipients
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •Adult Deceased Donor kidney recipients
排除标准
- •Live Kidney Donor Recipients
研究者
相似试验
进行中（未招募）
不适用
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
进行中（未招募）
不适用
Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study - NAPatients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities.MedDRA version: 8.1Level: LLTClassification code 10027703Term: Mismatched donor bone marrow transplantation therapyEUCTR2006-004101-26-BECHU Sart-Tilman
招募中
2 期
Mesenchymal stem cells for angiogenesis and neovascularisation in digital ulcers of systemic sclerosisSystemic scleroderma10003816sclerodermaNL-OMON47582niversitair Medisch Centrum Utrecht20
已完成
1 期
Mesenchymal Stem Cell therapy in COVID19COVID-19 Disease.COVID-19 DiseaseU07.02IRCT20200325046860N2Bagheiat-allah University of Medical Sciences5
招募中
1 期
Cell therapy with use of mesenchymal stem cells in infertile women with Thin EndometriumIRCT20230222057500N1Tehran University of Medical Sciences10